immunohistochemical assessment of her2 expression in gastric cancer in a cohort of 118 brazilian patients
Clicks: 172
ID: 188992
2013
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
172 views
27 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #37 of 53 articles by views in industrial and engineering chemistry research
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
INTRODUCTION: Recent studies indicate a role of human epidermal growth factor receptor type 2 (HER2) in the development of numerous types of human cancer, including gastric cancer, and its overexpression correlates with poor prognosis and increased aggressiveness of this neoplasm. OBJECTIVES: Identify and evaluate the immunohistochemical expression of HER2 in gastric cancer from biopsies, surgical resection specimens, lymph node metastasis and distant metastasis, and evaluate their correlation with currently known clinical and histopathological prognostic factors. METHODS: Samples from 118 patients of both sexes and all age groups diagnosed with gastric cancer were analyzed. Immunohistochemistry (IHQ) was performed using the HER2 antibody, and its evaluation was made according to the modified gastric cancer testing protocol, taking into account incomplete basolateral staining or only lateral staining. RESULTS: HER2 expression did not correlate with any histological prognostic factors or clinical outcome, except for the N stage. By comparing the HER2 expression in biopsies, surgical specimen, lymph node and metastasis, 88.1% were in agreement. CONCLUSION: As anti-HER2 therapies are becoming the standard of care in gastric cancer, currently available data indicate that IHQ should be used as the screening test, and the pathologist has an important role to ensure an accurate testing of HER2 status in these tumors. In addition, the HER2 status can be tested using the available samples from biopsies, surgical specimens, nodal and extranodal metastatic disease.
| Reference Key |
jung2013jornalimmunohistochemical
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Juliana Elizabeth Jung;Sérgio Ossamu Ioshii |
| Journal | industrial and engineering chemistry research |
| Year | 2013 |
| DOI |
10.1590/S1676-24442013000500010
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.